Dicerna Pharmaceuticals, Inc. (DRNA) shares are surging on Thursday morning trade after the company as it has signed a definitive agreement to be acquired by Novo Nordisk for $3.3 billion or $38.25 per share in cash. The transaction, expected to close in the fourth quarter of 2021, was unanimously approved by the Dicerna and Novo Nordisk boards. The acquisition of Dicerna is expected to accelerate Novo Nordisk's research within RNAi and expand the usage of the RNAi technology. It will combine Dicerna's state-of-the-art RNAi drug engine and intracellular delivery with Novo Nordisk's capabilities in disease biology understanding and tissue targeting through peptides and proteins.
Currently Dicerna shares are trading at $37.94, up 78.29 percent from the previous close of $21.28 on a volume of 12,136,761. For the 52-week period, the shares have traded in a range of $19.06-$40.14 on average volume of 796,087.
For comments and feedback contact: editorial@rttnews.com
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.